EyePoint's DURAVYU Misses Primary Endpoint in Phase 3 LUGANO Trial for Wet AMD
核心洞察
EyePoint, Inc. (搜索) announced topline results from LUGANO, the first pivotal Phase 3 trial of DURAVYU (vorolanib intravitreal insert) for wet age-related macular degeneration (搜索) (wet AMD).
DURAVYU did not meet the prespecified primary endpoint of change in best-corrected visual acuity versus on-label aflibercept in the full dataset.
Following the disclosure on August 17, 2026, EyePoint's stock price fell over 66%.
EyePoint, Inc. (搜索) (NASDAQ: EYPT) disclosed on August 17, 2026 that DURAVYU (vorolanib intravitreal insert) failed to meet its prespecified primary endpoint in LUGANO, the first pivotal Phase 3 clinical trial evaluating the therapy for the treatment of wet age-related macular degeneration (搜索) (wet AMD). The announcement triggered a sharp decline in the company's stock price, which fell over 66% following the news.
Trial Results
According to EyePoint's press release, DURAVYU did not meet the prespecified primary endpoint — change in best-corrected visual acuity versus on-label aflibercept — in the full dataset of the Phase 3 LUGANO trial in wet age-related macular degeneration (搜索). The LUGANO trial represented the first pivotal Phase 3 clinical trial for DURAVYU in this indication.
Market and Investor Impact
Following the disclosure of the disappointing clinical trial results, EyePoint's stock price fell over 66%. In response, Kessler Topaz Meltzer & Check, LLP (搜索) (KTMC), a nationally recognized securities litigation law firm, announced an investigation into potential violations of federal securities laws by EyePoint, Inc. (搜索) on behalf of investors who purchased or acquired EyePoint securities and experienced significant financial losses.
Investors who purchased or acquired EyePoint, Inc. (搜索) securities and experienced losses may have legal rights under federal securities laws. KTMC stated there is no cost or obligation to speak with an attorney regarding the matter.